Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortizatization of Intangibles (2023 - 2025)

Ani Pharmaceuticals' Amortizatization of Intangibles history spans 3 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 111.6% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached $11.6 million, up 221.19%, while the annual FY2024 figure was $13.6 million, 971.63% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was -$1.2 million at Ani Pharmaceuticals, down from $358000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $10.4 million in Q4 2024 and bottomed at -$1.2 million in Q4 2025.
  • The 3-year median for Amortizatization of Intangibles is $381000.0 (2023), against an average of $1.4 million.
  • The largest annual shift saw Amortizatization of Intangibles surged 2623.1% in 2024 before it crashed 111.6% in 2025.
  • A 3-year view of Amortizatization of Intangibles shows it stood at $381000.0 in 2023, then soared by 2623.1% to $10.4 million in 2024, then crashed by 111.6% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Amortizatization of Intangibles are -$1.2 million (Q4 2025), $358000.0 (Q3 2025), and $394000.0 (Q2 2025).